Apellis Pharmaceuticals, Inc. (APLS) has announced the immediate appointment of Craig Wheeler to its Board of Directors. Wheeler, the founder and CEO of Headwaters Biotech
Highlights LONDON, UK and Boston, MA, 7 April 2025 – Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces
WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted
Dr Heather Preston, seasoned healthcare investor with over 30 years’ experience as a scientist, physician, management consultant, and Board adviser, joins as Chair Cambridge, UK,
WALTHAM, Mass. October 26, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 3 VALIANT
29 October 2024, Dr. Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing on the
Hamburg, Germany, October 15th, 2024 – Topas Therapeutics today announced positive topline results from its Phase 2a trial evaluating lead candidate, TPM502, in patients with
Brighton, UK, 26 September 2024: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceuticalcompany dedicated to the discovery and development of novel therapies to improve the lives of
Dr Paulo Fontoura brings 20 years’ experience of working in the pharma industry, with the most recent 16 years focusing on translational medicine and clinical
Epidarex is pleased to announce the addition of Ryme Medical to our portfolio of medtech investments. Ryme is developing a unique catheter-based therapy that seeks to reduce